EGFR
All Product Categories
-
EGFR Inhibitors
(581)
View all products
-
EGFR Agonist
(1)
View all products
-
EGFR Antagonist
(1)
View all products
-
EGFR Activators
(5)
View all products
-
EGFR Modulators
(6)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(4)
View all products
-
EGFR Degraders
(22)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(13)
View all products
-
EGFR Related Products (757)
Related Products (757)
-
PACAP (1-38), human, ovine, rat-13C5,15N TFA
0 ImagesCat. No.: HY-P0221SSynonyms: Pituitary Adenylate Cyclase Activating Polypeptide 38-13C5,15N TFAPACAP (1-38), human, ovine, rat-13C5,15N (Pituitary Adenylate Cyclase Activating Polypeptide 38-13C5,15N) TFA is the 13C, 15N-labeled PACAP (1-38), human, ovine, rat (TFA) (HY-P0221A). PACAP (1-38), human, ovine, rat TFA is a PAC1 receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC50s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research.
-
LS-106
0 ImagesCat. No.: HY-164490LS-106 is an orally active and potent inhibitor against epidermal growth factor receptor (EGFR) . LS-106 exhibits antitumor activities both in vitro and in vivo. LS-106 inhibits the kinase activities of EGFR19del/T790M/C797S and EGFRL858R/T790M/C797S with IC50 values of 2.4 nmol/L and 3.1 nmol/L, respectively, which is more potent than Osimertinib (HY-15772). LS-106 induces Apoptosis, suppresses cell proliferation of tumor cells harboring EGFR19del/T790M/C797S and leas to significant tumor regression in a C797S-mutant xenograft model.
-
VEGFR-IN-4
0 ImagesCat. No.: HY-162099CAS No.: 3000483-29-1VEGFR-IN-4 (Compound 6e) is an epidermal growth factor receptor (EGFR) inhibitor. VEGFR-IN-4 has potent antiproliferative activity with an IC50 value of 24.6nM against HCC827 cells.
-
Asterriquinone
0 ImagesCat. No.: HY-N14349CAS No.: 60696-52-8Synonyms: ARQ; Asterriquinone SU5504Asterriquinone (ARQ), a Asterriquinone analog, is a Grb-2 binding inhibitor. Asterriquinone inhibits the Grb-2 binding activity to tyrosine phosphorylated EGFR, with an IC50 of 8.37 μM. Asterriquinone is a HIV1 reverse transcriptase inhibitor with a Ki of 2.3 μM. Asterriquinone also inhibits Grb-7 and PLC-γ binding activities..
-
EGFR-IN-219
0 ImagesCat. No.: HY-189466EGFR-IN-219 is an EGFR inhibitor. EGFR-IN-219 induces Apoptosis and G0/G1 cell cycle arrest. EGFR-IN-219 exhibits selective anticancer activity against lung adenocarcinoma. EGFR-IN-219 can be used for research on non-small cell lung cancer.
-
EGFR-IN-50
0 ImagesCat. No.: HY-146210CAS No.: 2044508-48-5
-
DCBA (Standard)
0 ImagesCat. No.: HY-136612RCAS No.: 72236-23-8DCBA (Standard) is the analytical standard of DCBA (HY-136612). This product is intended for research and analytical applications. DCBA is the major urinary oxidative metabolite of the insect repellent DEET (HY-B0978). DCBA targets EGFR. DCBA exposure is significantly positively correlated with the risk of liver fibrosis. DCBA can be used in liver fibrosis research.
-
Cucurbitacin IIa (Standard)
0 ImagesCat. No.: HY-N1988RCAS No.: 58546-34-2Synonyms: Hemslecin A (Standard)Cucurbitacin IIa (Hemslecin A) (Standard) is the analytical standard for Cucurbitacin IIa (HY-N1988). This product is used for research and analytical applications. Cucurbitacin IIa is an orally active, blood-brain barrier-penetrating EGFR inhibitor with an IC50 of 1.455 nM for human EGFR. Cucurbitacin IIa induces caspase-3 dependent cell apoptosis, downregulates survivin expression, enhances autophagy levels, disrupts the actin cytoskeleton through actin aggregation, blocks the cell cycle at the G2/M phase, and inhibits the EGFR-MAPK signaling pathway to exert anti-inflammatory activity. Cucurbitacin IIa can be used in research on inflammatory-related diseases, depression, and non-small cell lung cancer and other cancers.
-
N-Desmethyl dosimertinib
0 ImagesCat. No.: HY-142283BSCAS No.: 2719691-00-4Synonyms: N-Desmethyl Osimertinib-d5; N-Desmethyl AZD-9291-d5; N-Desmethyl Mereletinib-d5N-Desmethyl dosimertinib is the deuterium labeled N-Desmethyl dosimertinib.
-
NSC381467
0 ImagesCat. No.: HY-144444CAS No.: 1033006-96-0
-
Erbb4 Mouse Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS04473Erbb4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Erbb4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
Jaceidin
0 ImagesCat. No.: HY-114535CAS No.: 10173-01-0Jaceidin is a promising lead molecule for potent VEGFR inhibitor with excellent membrane permeability and oral bioavailability. Jaceidin exhibits anti-tumor activities.
-
SKS-927
0 ImagesCat. No.: HY-10188CAS No.: 885482-95-1SKS-927 is a Src kinase inhibitor, with an IC50 value of 3.9 nM. SKS-927 inhibits the proliferation of Src-transformed rat fibroblasta, with an IC50 value of 73 nM. SKS-927 exhibits an IC50 value of 720 nM against EGFR. SKS-927 can be used for the study of cancer and osteoporosis.
-
EGFR-IN-179
0 ImagesCat. No.: HY-178442CAS No.: 3078678-28-8EGFR-IN-179 (Compound 8d) is an EGFR inhibitor (IC50: 0.068 μM for EGFR L858R/T790M/C797S; 2.56 μM for EGFR-WT-TK). EGFR-IN-179 has anticancer activity against non-small cell lung cancer.
-
Anticancer agent 271
0 ImagesCat. No.: HY-173367Anticancer agent 271 (compound 5C) has antiproliferative activity against lung (A549), colon (Caco-2) cancer cell lines, and human lung fibroblast (WI38) with an IC50 value of 9.18 μM on A549 cells. Anticancer agent 271 downregulates PI3K and mTOR gene expression that can be used for cancer research.
-
SRT6
0 ImagesCat. No.: HY-175809Purity: 99.90%SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44+ breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer.
-
Anticancer agent 133
0 ImagesCat. No.: HY-149344CAS No.: 2758905-51-8Anticancer agent 133 (compound Rh2) is an anti-cancer agent with cytotoxic and antimetastatic activities. Anticancer agent 133 induces cell cycle arrest, apoptosis, and autophagy. Anticancer agent 133 also inhibits cell metastasis via suppression of EGFR expression mediated by FAK-regulated integrin β1.
-
MHES0488A
0 ImagesCat. No.: HY-P991236Synonyms: DHES0815A antibody; RG-6148 antibodyMHES0488A is a selective humanized antibody that targets HER2 with a KD value of 0.8 nM. MHES0488A is an antibody part of DHES0815A. MHES0488A is internalized by cells and transported to lysosomes, and then releases PBD-monoamide that enters the nucleus, alkylates DNA and induces DNA damage and apoptosis. MHES0488A is promising for research of cancers, such as HER2-positive breast cancer and gastric cancer.
-
O-Desmethyl gefitinib-d6
0 ImagesCat. No.: HY-100064S1O-Desmethyl gefitinib-d6 is the deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits EGFR with an IC50 of 36 nM in subcellular assays.
